Analysis of pairwise linkage disequilibrium (LD) coefficients and statistics (D′) for lung cancer patients (below diagonal) and control (above diagonal) among five SNPs.

<p>Analysis of pairwise linkage disequilibrium (LD) coefficients and statistics (D′) for lung cancer patients (below diagonal) and control (above diagonal) among five SNPs.</p

Genotype and allele frequencies of <i>UGT1A6</i> SNPs in both first and second cohorts.

<p>Genotype and allele frequencies of <i>UGT1A6</i> SNPs in both first and second cohorts.</p

Baseline characteristics of Lung cancer patients and controls.

<p>*Smoking history was not obtained for the 100 controls.</p

Haplotype frequency estimates and significant levels of case-control comparison from permutation tests.

*<p>P<0.05,</p>**<p>P<0.01,</p>***<p>P<0.001.</p

In vitro functional characterization of UGT1A6 105C>T polymorphism.

<p>UGT1A6*1 and UGT1A6 105TT constructs were stably transfected into HEK293 cells. (<b>A</b>) Cells were harvested upon treatment with ActD at different time point up to 24 hours. The data plotted are time course changes in the remaining amount of UGT1A6 mRNA after ActD treatment. There was significantly higher mRNA level in UGT1A6 105TT than UGT1A6*1 transfected cells at 4 hours (p = 0.039) and 8 hours (p = 0.004) after treatment with ActD. (<b>B</b>) Western blot analysis. Cell lysate used was from 5×10⁵ cells at the indicated times (0, 8, 24 and 48 hours) after treatment with ActD. There was a down-regulation in protein expression in UGT1A6*1 as compared to UGT1A6 variant at 48 hours after treatment with ActD. UGT1A6 activity was assessed by evaluating the production of serotonin glucuronide using lysate from variant UGT1A6 (VT) and UGT1A6*1 (WT) at 0 hour (<b>C</b>) and 48 hours (<b>D</b>) after ActD treatment, with substrate concentrations varied from 0.5 to 30 mM serotonin. Activities are expressed as reaction velocity (nanomoles of serotonin glucuronide formed per minute per milligram of protein).</p

Exemestane major metabolism pathway.

<p>Exemestane major metabolism pathway.</p

Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.

<p>Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.</p

Accuracy and Precision of Dilution Procedure for Exe.

<p>*Expressed as mean percentage (n = 4) of the mean value measured over the nominal value</p><p>^#Expressed as percentage of the standard deviation divided by the mean</p><p>Accuracy and Precision of Dilution Procedure for Exe.</p

Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.

<p>Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.</p

Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at 100 ng/mL as internal standards.

<p>Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at 100 ng/mL as internal standards.</p